공고 • Aug 19
Enhanced Group Announces Enhanced OS The AI Powered Operating System For Delivering Human Potential Enhanced Group announced Enhanced OS, an artificial intelligence-powered platform designed to become the operating system for human potential. Enhanced OS is scheduled to launch during 2026, with additional features, access, and full commercial details to be shared in the coming months. Enhanced OS will provide the same tools once reserved for elite athletes: a personalized plan, protocol, doctor, game, and coach all powered by AI with the highest levels of medical supervision and access to regulated prescription therapy products. Enhanced OS is designed to learn who a member is, what they're trying to achieve, and where they're starting from. It then builds a personalized path forward that regularly changes and optimizes using insights drawn from Enhanced’s elite athletic performance team. Enhanced OS is designed to: Learn continuously from a customer’s medical records, biomarkers, and wearable data to refine each member's plan over time; Combine AI and clinical expertise, AI drafts, monitors, and recommends, while licensed doctors take the baton and retain all clinical decision-making. Each of the data points generated through the clinical trial will be training data, to help make this the best personalization platform in the market; Pair every plan with human accountability, encouraging members to test their progress and development in community-led participation events such as run-clubs; Bridge the digital and physical, offering the ability to link each member's health journey to a community, competition, or live events they themselves select because transformation won’t happen entirely on a screen. The Company plans to offer a tier of the OS system that will remain free indefinitely, serving as the front door to the Enhanced ecosystem and giving members a reason to get educated and gain greater trust before any purchase is made. From there, enhancement will exist on a spectrum. For some, that means personalized supplementation, training, and nutrition anchored to a real event like a marathon or competition. For others, the spectrum may include a full clinical protocol built around individual biomarkers and goals. Enhanced OS is built to deliver across this spectrum of human optimization at any level a consumer wants. Enhanced intends to keep its customers throughout their health journey, by adapting as their goals, circumstances, and physiology evolve, rather than treating health as a one-time transaction. Members who experience real results create advocacy no advertising budget can buy. 공고 • Aug 07
Enhanced Group Inc. to Report Q2, 2026 Results on Aug 13, 2026 Enhanced Group Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026 Board Change • Jul 30
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공고 • Jun 30
Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced Platform Enhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform. Board Change • Jun 29
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 공고 • Jun 15
Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group Limited Enhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors. 
